Biomarker & Intervention Discovery

Endometriosis

This page lists 11 druggable gene targets, 42 approved or trial-tested drug candidates and 15 recent clinical trials for Endometriosis, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs820.9KWHO GHE 2021 · all ages
Global DALYs27.02MWHO GHE 2021 · worldwide
Global mortality7,743 deaths/yrWHO GHE 2021 · worldwide
NIH funding$37MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionEndometriosis lesions may partially regress after menopause; spontaneous resolution of symptoms rare; recurrence rate…
Best-intervention remissionExcision surgery achieves pain relief in 60-80% at 6 months but 50% recurrence at 5 years; GnRH agonists + add-back…
Gap sizeVery large — diagnostic delay averages 7-10 years from symptom onset; no disease-modifying treatment; high recurrence…
Primary barrierbiological + practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Endometriosis lesions may partially regress after menopause; spontaneous resolution of symptoms rare; recurrence rate after surgery 20-40% at 2 years and 50-60% at 5 years
Best-intervention remission
Excision surgery achieves pain relief in 60-80% at 6 months but 50% recurrence at 5 years; GnRH agonists + add-back therapy: 70-90% pain reduction but oestrogen-deprivation side effects; combined OCP: 50-60% pain reduction; elagolix (Orilissa): 43% reduction in dysmenorrhoea vs placebo (ELARIS EM-I)
Gap size
Very large — diagnostic delay averages 7-10 years from symptom onset; no disease-modifying treatment; high recurrence after surgery
Primary barrier
biological + practice
Diagnostic delay of 7-10 years is the largest modifiable factor; endometriosis dismissed as 'normal period pain'; no non-surgical diagnostic test; all medical treatments are suppressive not curative; recurrence after surgery is universal without continued medical suppression

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CYP19A1 187ESR1 386ESR2 243GNRHR 221HSD17B1 169IL6 181NGF 9PGR 158PTGS2 309TNF 287VEGFA 207
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AZALANSTAT ↓ inhibits Mechanistic 7.6 nM (Ki)
NARINGENIN ? unclear Mechanistic
TESTOLACTONE ↓ inhibits Mechanistic 35000.0 nM (Ki)
ATROPINE ? unclear Mechanistic
FADROZOLE ↓ inhibits Mechanistic
EXEMESTANE ↓ inhibits Mechanistic
AMINOGLUTETHIMIDE ↓ inhibits Mechanistic 600.0 nM (Ki)
LIOTHYRONINE ? unclear Mechanistic
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ? unclear Mechanistic
LIAROZOLE ? unclear Mechanistic
CHEMBL:CHEMBL1077603 ? unclear Mechanistic
AZTREONAM ? unclear Mechanistic
GONADOTROPIN-RELEASING HORMONE ANALOG ? unclear Mechanistic
ISOPROTERENOL ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
TAMOXIFEN ? unclear Mechanistic
LETROZOLE ↓ inhibits Mechanistic
ANASTROZOLE ↓ inhibits Mechanistic
ATAMESTANE ? unclear Mechanistic
FORMESTANE ? unclear Mechanistic 410.0 nM (IC50)
PHYTOESTROGEN ? unclear Mechanistic
FADROZOLE HYDROCHLORIDE ↓ inhibits Mechanistic
PHENYTOIN SODIUM ? unclear Mechanistic
ANABOLIC STEROID ? unclear Mechanistic
TESTOSTERONE ENANTHATE ? unclear Mechanistic
CHEMBL:CHEMBL572637 ? unclear Mechanistic
ADENOVIRUS VECTOR ? unclear Mechanistic
ISOPROPYL ALCOHOL ? unclear Mechanistic
BIOFLAVONOID ? unclear Mechanistic
ALENDRONATE SODIUM ? unclear Mechanistic
CAPECITABINE ? unclear Mechanistic
GENISTEIN ? unclear Mechanistic
NONSTEROIDAL ANTIINFLAMMATORY DRUG ? unclear Mechanistic
ENVIRONMENTAL ESTROGEN ? unclear Mechanistic
ANDROSTENEDIONE ? unclear Mechanistic
OPIATE ? unclear Mechanistic
FLUOROURACIL ? unclear Mechanistic
NORENDOXIFEN ↓ inhibits Mechanistic
ENDOXIFEN ↓ inhibits Mechanistic

Showing top 40 of 187 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ESTRONE ↑ activates Mechanistic 480.0 nM (EC50)
EVEROLIMUS ? unclear Mechanistic
ANASTROZOLE ? unclear Mechanistic
SIVIFENE ? unclear Mechanistic
ARZOXIFENE ~ modulates Mechanistic
ENDOXIFEN ↓ inhibits Mechanistic
OSPEMIFENE ↓ inhibits Mechanistic
RALOXIFEN ? unclear Mechanistic
FULVESTRANT ↓ inhibits Mechanistic 6.0 nM (IC50)
INAVOLISIB ? unclear Mechanistic
TESTOSTERONE PROPIONATE ? unclear Mechanistic
PHENYLMERCURIC ACETATE ? unclear Mechanistic
ESTRADIOL CYPIONATE ↑ activates Mechanistic
ESTROGEN ? unclear Mechanistic
METHOXSALEN ? unclear Mechanistic
BORIC ACID ? unclear Mechanistic
IMLUNESTRANT ↓ inhibits Mechanistic
PROTOAPIGENONE ? unclear Mechanistic
CLOMIPHENE CITRATE ? unclear Mechanistic
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic
NERATINIB ? unclear Mechanistic
ALACHLOR ? unclear Mechanistic
METHAMPHETAMINE ? unclear Mechanistic
OCHRATOXIN A ? unclear Mechanistic
CETRIMONIUM BROMIDE ? unclear Mechanistic
EXEMESTANE ? unclear Mechanistic
GW7647 ? unclear Mechanistic
NORGESTREL ? unclear Mechanistic
AMCENESTRANT ↓ inhibits Mechanistic
LETROZOLE ? unclear Mechanistic
PROGESTERONE ? unclear Mechanistic
DIETHYLSTILBESTROL ↑ activates Mechanistic 12.0 nM (EC50)
ESTRIOL ↑ activates Mechanistic
16Α-HYDROXYESTRONE ↑ activates Mechanistic
BRILANESTRANT ? unclear Mechanistic
LEVONORGESTREL ? unclear Mechanistic
ACOLBIFENE ? unclear Mechanistic
PROPYLPYRAZOLETRIOL ↑ activates Mechanistic
ESTRADIOL VALERATE ↑ activates Mechanistic
MEGESTROL ? unclear Mechanistic

Showing top 40 of 386 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
OSPEMIFENE ↓ inhibits Mechanistic
ESTRONE ↑ activates Mechanistic 1135.0 nM (EC50)
LAPATINIB ? unclear Mechanistic
ESTRADIOL VALERATE ↑ activates Mechanistic
FULVESTRANT ↓ inhibits Mechanistic 7.0 nM (IC50)
DIETHYLSTILBESTROL ↑ activates Mechanistic 9.0 nM (EC50)
RIBOCICLIB ? unclear Mechanistic
PERTUZUMAB ? unclear Mechanistic
CHEMBL:CHEMBL1222035 ? unclear Mechanistic
ALENDRONATE SODIUM ? unclear Mechanistic
LASOFOXIFENE TARTRATE ~ modulates Mechanistic
LASOFOXIFENE ↑ activates Mechanistic
TAMOXIFEN ↓ inhibits Mechanistic
BAZEDOXIFENE ACETATE ~ modulates Mechanistic
RALOXIFEN ? unclear Mechanistic
FERB 033 ↑ activates Mechanistic
ERTEBEREL ? unclear Mechanistic
ABEMACICLIB ? unclear Mechanistic
ESTRIOL ↑ activates Mechanistic
GEMCITABINE ? unclear Mechanistic
ALLYLESTRENOL ↑ activates Mechanistic
R,R-THC ↓ inhibits Mechanistic
IXABEPILONE ? unclear Mechanistic
4-HYDROXYTAMOXIFEN ↓ inhibits Mechanistic
NORENDOXIFEN ↑ activates Mechanistic
PRINABEREL ↑ activates Mechanistic
WAY200070 ↑ activates Mechanistic
(S)-LIQUIRITIGENIN ↑ activates Mechanistic
EVEROLIMUS ? unclear Mechanistic
GOSERELIN ? unclear Mechanistic
TRASTUZUMAB ? unclear Mechanistic
OLAPARIB ? unclear Mechanistic
MF101 ↑ activates Mechanistic
ESTETROL ↑ activates Mechanistic
FAM-TRASTUZUMAB DERUXTECAN-NXKI ? unclear Mechanistic
CHLOROTRIANISENE ~ modulates Mechanistic
NARINGENIN ? unclear Mechanistic
CAPIVASERTIB ? unclear Mechanistic
INAVOLISIB ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ~ modulates Mechanistic 43.0 nM (IC50)

Showing top 40 of 243 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LEUPROLIDE MESYLATE ↑ activates Mechanistic
[TRP8]GNRH ↑ activates Mechanistic
ZOPTARELIN DOXORUBICIN ? unclear Mechanistic
LEUPROLIDE ACETATE ↑ activates Mechanistic
GONADORELIN ? unclear Mechanistic
NBI-42902 ↓ inhibits Mechanistic
T-98475 ↓ inhibits Mechanistic
GANIRELIX ACETATE ↓ inhibits Mechanistic
5-(N,N-HEXAMETHYLENE)-AMILORIDE ~ modulates Mechanistic
HISTRELIN ↑ activates Mechanistic
GONADORELIN ACETATE ↑ activates Mechanistic
RELUGOLIX ↓ inhibits Mechanistic
LINZAGOLIX ↓ inhibits Mechanistic
ELAGOLIX ↓ inhibits Mechanistic
WAY-207024 ↓ inhibits Mechanistic
[TYR8]GNRH ↑ activates Mechanistic
GONADORELIN HYDROCHLORIDE ↑ activates Mechanistic
D-23487 ↓ inhibits Mechanistic
NAFARELIN ↑ activates Mechanistic
OPIGOLIX ↓ inhibits Mechanistic
DANAZOL ? unclear Mechanistic
[SER8]GNRH ↑ activates Mechanistic
GNRH I ↑ activates Mechanistic
FD-1 ↓ inhibits Mechanistic
SUFUGOLIX ↓ inhibits Mechanistic
DESLORELIN ACETATE ↑ activates Mechanistic
GNRH II ↑ activates Mechanistic
HISTERELIN ↑ activates Mechanistic
TRIPTORELIN PAMOATE ? unclear Mechanistic
[125I][TYR5,DALA6,NMELEU7,PRO9-NET]GNRH ↑ activates Mechanistic
HISTRELIN ACETATE ↑ activates Mechanistic
UCALOLICTIDE ? unclear Mechanistic
DEGARELIX ACETATE ↓ inhibits Mechanistic
ALARELIN ↑ activates Mechanistic
GOSERELIN ↑ activates Mechanistic
FERTIRELIN ↑ activates Mechanistic
ACYLINE ? unclear Mechanistic
GNRH III ↑ activates Mechanistic
ITURELIX ↓ inhibits Mechanistic
NAFARELIN ACETATE ↑ activates Mechanistic

Showing top 40 of 221 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL1627453 ↓ inhibits Mechanistic 420.0 nM (IC50)
CHEMBL1627450 ↓ inhibits Mechanistic 460.0 nM (IC50)
CHEMBL1627455 ↓ inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL1627884 ↓ inhibits Mechanistic 4300.0 nM (IC50)
CHEMBL1627451 ↓ inhibits Mechanistic 1150.0 nM (IC50)
CHEMBL307621 ↓ inhibits Mechanistic 59000.0 nM (Ki)
CHEMBL75893 ↓ inhibits Mechanistic 65000.0 nM (Ki)
CHEMBL76061 ↓ inhibits Mechanistic 2800.0 nM (Ki)
CHEMBL1627749 ↓ inhibits Mechanistic 37.0 nM (IC50)
CHEMBL1627752 ↓ inhibits Mechanistic 27.0 nM (IC50)
CHEMBL1627742 ↓ inhibits Mechanistic 290.0 nM (IC50)
CHEMBL1627759 ↓ inhibits Mechanistic 10000.0 nM (IC50)
CHEMBL369897 ↓ inhibits Mechanistic 110.0 nM (IC50)
CHEMBL1627756 ↓ inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL198223 ↓ inhibits Mechanistic 180.0 nM (IC50)
CHEMBL198613 ↓ inhibits Mechanistic 2750.0 nM (IC50)
CHEMBL365752 ↓ inhibits Mechanistic 920.0 nM (IC50)
CHEMBL194579 ↓ inhibits Mechanistic 530.0 nM (IC50)
CHEMBL197056 ↓ inhibits Mechanistic 730.0 nM (IC50)
CHEMBL372540 ↓ inhibits Mechanistic 1850.0 nM (IC50)
CHEMBL381466 ↓ inhibits Mechanistic 950.0 nM (IC50)
CHEMBL434950 ↓ inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL364060 ↓ inhibits Mechanistic 780.0 nM (IC50)
CHEMBL438624 ↓ inhibits Mechanistic 880.0 nM (IC50)
CHEMBL194690 ↓ inhibits Mechanistic 300.0 nM (IC50)
CHEMBL370570 ↓ inhibits Mechanistic 13500.0 nM (IC50)
CHEMBL370571 ↓ inhibits Mechanistic 6900.0 nM (IC50)
CHEMBL382114 ↓ inhibits Mechanistic 90.0 nM (IC50)
CHEMBL331544 ↓ inhibits Mechanistic 310.0 nM (IC50)
CHEMBL170583 ↓ inhibits Mechanistic 120.0 nM (IC50)
CHEMBL369588 ↓ inhibits Mechanistic 430.0 nM (IC50)
CHEMBL332756 ↓ inhibits Mechanistic 93.0 nM (IC50)
CHEMBL371948 ↓ inhibits Mechanistic 52.0 nM (IC50)
CHEMBL372560 ↓ inhibits Mechanistic 140.0 nM (IC50)
CHEMBL198558 ↓ inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL1628005 ↓ inhibits Mechanistic 340.0 nM (IC50)
CHEMBL1627790 ↓ inhibits Mechanistic 320.0 nM (IC50)
ESTRONE ↓ inhibits Mechanistic 330.0 nM (IC50)
CHEMBL1628135 ↓ inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL1628021 ↓ inhibits Mechanistic 380.0 nM (IC50)

Showing top 40 of 169 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLAZAKIZUMAB ↓ inhibits Mechanistic
MIDOSTAURIN ? unclear Mechanistic
ECHINACEA EXTRACT ? unclear Mechanistic
NELFINAVIR ? unclear Mechanistic
SELECTIVE ESTROGEN RECEPTOR MODULATOR ? unclear Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
OLOKIZUMAB ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
SITAGLIPTIN ? unclear Mechanistic
METRONIDAZOLE ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
PACIBEKITUG ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
SIRUKUMAB ↓ inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
SAFINGOL ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
C326 ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
ZILTIVEKIMAB ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
OSIMERTINIB ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
ALOGLIPTIN ? unclear Mechanistic
TENELIGLIPTIN ? unclear Mechanistic
CHINESE HERBS ? unclear Mechanistic
TOCILIZUMAB ? unclear Mechanistic
LINAGLIPTIN ? unclear Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
VILDAGLIPTIN ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SAQUINAVIR ? unclear Mechanistic
PAREGORIC ? unclear Mechanistic

Showing top 40 of 181 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FASINUMAB ? unclear Mechanistic
CERE-110 ? unclear Mechanistic
TANEZUMAB ? unclear Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB ↓ inhibits Mechanistic
PG-110 ↓ inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
MEDI-578 ↓ inhibits Mechanistic
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ETHYNODIOL DIACETATE ↑ activates Mechanistic
MIFEPRISTONE ↓ inhibits Mechanistic 0.028 nM (IC50)
LAPATINIB ? unclear Mechanistic
ETONOGESTREL ↑ activates Mechanistic
GESTODENE ↑ activates Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
PROGESTERONE ↑ activates Mechanistic 2.9 nM (EC50)
NERATINIB ? unclear Mechanistic
NORELGESTROMIN ↑ activates Mechanistic
ZK112993 ↓ inhibits Mechanistic
ASOPRISNIL ↓ inhibits Mechanistic
NORGESTIMATE ↑ activates Mechanistic
TELAPRISTONE ? unclear Mechanistic
CYPROTERONE ACETATE ↑ activates Mechanistic
CHLORMADINONE ACETATE ~ modulates Mechanistic
TAMOXIFEN ? unclear Mechanistic
EXEMESTANE ? unclear Mechanistic
PERTUZUMAB ? unclear Mechanistic
PROGESTIN ? unclear Mechanistic
MEGESTROL ACETATE ↑ activates Mechanistic
PROGESTOGEN ? unclear Mechanistic
LONAPRISAN ↓ inhibits Mechanistic
NORGESTREL ↑ activates Mechanistic
NOMEGESTROL ↑ activates Mechanistic
MEDROXYPROGESTERONE ACETATE ↑ activates Mechanistic 0.15 nM (EC50)
ULIPRISTAL ~ modulates Mechanistic
DYDROGESTERONE ↑ activates Mechanistic
NORETHYNODREL ↑ activates Mechanistic
ERIBULIN ? unclear Mechanistic
ESTRADIOL VALERATE/DIENOGEST ? unclear Mechanistic
NORETHINDRONE ACETATE ↑ activates Mechanistic
PROMEGESTONE ↑ activates Mechanistic
CHEMBL:CHEMBL2059711 ? unclear Mechanistic
LETROZOLE ? unclear Mechanistic
DANAZOL ↑ activates Mechanistic
ULIPRISTAL ACETATE ↓ inhibits Mechanistic
APR19 ↓ inhibits Mechanistic
PALBOCICLIB ? unclear Mechanistic
PF-05019702 ↓ inhibits Mechanistic
VILAPRISAN ? unclear Mechanistic

Showing top 40 of 158 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN PYRAZOLE ? unclear Mechanistic
CAPECITABINE ? unclear Mechanistic
DIFLUNISAL ↓ inhibits Mechanistic
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50)
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic
DEXIBUPROFEN ↓ inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
ESFLURBIPROFEN ↓ inhibits Mechanistic
NAPROXEN ETEMESIL ? unclear Mechanistic
SUPROFEN ↓ inhibits Mechanistic
PEPTIDE 30 [PMID: 27019010] ↓ inhibits Mechanistic
NEPAFENAC ↓ inhibits Mechanistic
APRICOXIB ↓ inhibits Mechanistic
APAZONE ↓ inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
KETOPROFEN ↓ inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NS-398 ↓ inhibits Mechanistic
NABUMETONE ↓ inhibits Mechanistic
SULINDAC ↓ inhibits Mechanistic
ETODOLAC ↓ inhibits Mechanistic
MEFENAMIC ACID ↓ inhibits Mechanistic
DICLOFENAC SODIUM ↓ inhibits Mechanistic
ETORICOXIB ↓ inhibits Mechanistic
VALDECOXIB ↓ inhibits Mechanistic
IBUFENAC ↓ inhibits Mechanistic
DEXKETOPROFEN ↓ inhibits Mechanistic
GLAFENINE ↓ inhibits Mechanistic
COMPOUND 9 [KUMAR ET AL., 2019] ↓ inhibits Mechanistic
RESVERATROL ↓ inhibits Mechanistic
SWE101 ↓ inhibits Mechanistic
INDOMETHACIN ↓ inhibits Mechanistic 5.9 nM (IC50)
NAPROXCINOD ↓ inhibits Mechanistic
HR1405-01 ↓ inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic
COMPOUND 12A [PMID: 29031075] ↓ inhibits Mechanistic
TOLMETIN SODIUM ↓ inhibits Mechanistic
OXYPHENBUTAZONE ↓ inhibits Mechanistic
DICLOFENAC POTASSIUM ↓ inhibits Mechanistic

Showing top 40 of 309 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DICLOFENAC SODIUM ? unclear Mechanistic
RDP58 ? unclear Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ORTATAXEL ? unclear Mechanistic
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic
OZORALIZUMAB ↓ inhibits Mechanistic
THALIDOMIDE ? unclear Mechanistic
HUANG LIAN ? unclear Mechanistic
GOLIMUMAB ↓ inhibits Mechanistic
CYCLOSPORINE ? unclear Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
HALOFUGINONE ? unclear Mechanistic
ETANERCEPT ↓ inhibits Mechanistic
ISIS 104838 ? unclear Mechanistic
GEMCITABINE ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
DIDANOSINE ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SOBLIDOTIN ? unclear Mechanistic
STAVUDINE ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
MEROPENEM ANHYDROUS ? unclear Mechanistic
AMPHOTERICIN B LIPOSOMAL ? unclear Mechanistic
MIDAZOLAM HYDROCHLORIDE ? unclear Mechanistic
RIFAMPIN ? unclear Mechanistic
AVX-470 ? unclear Mechanistic
KETOROLAC TROMETHAMINE ? unclear Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
BENZO[E]PYRENE ? unclear Mechanistic
ETHAMBUTOL HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ↓ inhibits Mechanistic
SPIRONOLACTONE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
MITOMYCIN C ANALOG KW-2149 ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
ABBV-3373 ~ modulates Mechanistic
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic

Showing top 40 of 287 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
BEVASIRANIB ? unclear Mechanistic
RANIBIZUMAB ↓ inhibits Mechanistic
CP-547632 ? unclear Mechanistic
EW-A-401 ? unclear Mechanistic
BEVACIZUMAB 111IN ~ modulates Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
PEGAPTANIB ↓ inhibits Mechanistic
DEXAMETHASONE ? unclear Mechanistic
SQUALAMINE ? unclear Mechanistic
AFLIBERCEPT ↓ inhibits Mechanistic
PAZOPANIB ? unclear Mechanistic
BEVACIZUMAB GAMMA ~ modulates Mechanistic
CILOSTAZOL ? unclear Mechanistic
ADALIMUMAB ? unclear Mechanistic
MUPARFOSTAT ↓ inhibits Mechanistic
SILDENAFIL ? unclear Mechanistic
PENTOSAN POLYSULFATE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
RISUTEGANIB ? unclear Mechanistic
SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088 ? unclear Mechanistic
PHENETHYL ISOTHIOCYANATE ? unclear Mechanistic
EMVODODSTAT ? unclear Mechanistic
CARFILZOMIB ? unclear Mechanistic
FARICIMAB ↓ inhibits Mechanistic
ALBUTEROL SULFATE ? unclear Mechanistic
LENALIDOMIDE ↓ inhibits Mechanistic
SUNITINIB ? unclear Mechanistic
SHARK CARTILAGE EXTRACT AE-941 ? unclear Mechanistic
NM-3 ? unclear Mechanistic
DILPACIMAB ? unclear Mechanistic
PEMETREXED DISODIUM ? unclear Mechanistic
BI-836880 ? unclear Mechanistic
BROLUCIZUMAB ↓ inhibits Mechanistic
DOMATINOSTAT ? unclear Mechanistic
ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC ? unclear Mechanistic
VEGF/HGF-TARGETING DARPIN MP0250 ? unclear Mechanistic
WARFARIN ? unclear Mechanistic
CELECOXIB ? unclear Mechanistic
NAVICIXIZUMAB ? unclear Mechanistic
VEGLIN ? unclear Mechanistic

Showing top 40 of 207 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Endometriosis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07755956 Phase: 1 Started: 2026-10-31

The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check ho...

NCT06543550 Phase: 4 Started: 2024-07-30

This study aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.

NCT07260669 Phase: 2 Started: 2025-10-15

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

NCT03746535 Phase: Early 1 Started: 2022-07-01

To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

NCT06477406 Phase: 2 Started: 2024-02-27

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectru...

NCT07509411 Phase: 2 Started: 2025-08-15

This prospective study targets infertile women with endometriosis (EM) who have experienced a previously failed Intracytoplasmic Sperm Injection (ICSI) trial. Using the P-I-C-O framework, the study evaluates whether the administration of an anti-TNF-α therapy (Intervention) 4-5 days before a frozen ...

NCT07318688 Phase: 3 Started: 2026-01-29

A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension

NCT07728695 Phase: 1/2 Started: 2026-09

Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy fo...

NCT07696351 Phase: 4 Started: 2025-08-01

Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endomet...

NCT06439524 Phase: 3 Started: 2024-08-15

The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an F...

NCT04333576 Phase: 3 Started: 2020-08-10

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives ...

NCT05570786 Phase: 2 Started: 2023-02-13

Pelvic pain is considered a symptom of multifactorial origin among which Endometriosis is the main gynecological cause affecting 5-10% of worldwide women in their reproductive years, negatively impacting their quality of life and work efficiency. Treatment of endometriosis-associated pelvic pain is ...

NCT05560646 Phase: 2 Started: 2022-10-25

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

NCT07015268 Phase: 3 Started: 2025-06-09

To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.

NCT07100782 Phase: 3 Started: 2025-12-08

The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.


Agents Found By Disease-Level Search

Searched directly from “Endometriosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

42 agents shown (approved or with trial evidence) — 40 not found by the gene-target search above.

Elagolix

Phase 3 · 9 trials · source: ClinicalTrials.gov, Open Targets
NCT01403038 NCT01403038 NCT01403038

GnRH-analogueNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02091557 NCT02086279

Letrozole

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05487092 NCT00240942

BAY1817080 - Formulation ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03773068

BAY1817080 - Formulation BNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03773068

Closure of the Vaginal Cuff after Total HysterectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06024109

Alcohol sclerotherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02669628

Circulating DNA analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07471373

Vaginal microbiota analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07471373

Endometrial microbiota analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07471373

Intestinal microbiota analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07471373

Exposure to endocrine disruptors analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07471373

Specialized kitNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07683468

conventional laparoscopic hysterectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00485355

robotic assisted laparoscopic hysterectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00485355

Human Chorionic Gonadotropin (hCG)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04071574

GonadotropinsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04071574

GNRH-A TriptorelinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04071574

GnRH antagonistNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04071574

Laparoscopic cystectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07004959

Rectal water-contrast transvaginal ultrasonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04296760

SonovaginographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04296760

BAY2328065 LSFNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04027192

BAY2328065 tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04027192

MidazolamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04027192

ENDO 1/ENDO 2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02437175

Tab.Dienogest 2 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07770594

Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07770594

Melatonin 10 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03782740

Melatonin 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03782740

Rectal/colorectal segmental resectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01291576

Rectal nodule excisionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01291576

Food supplement (T1675)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07393958

DiathermyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06414083

Argon Beam CoagulatorNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06414083

Ziwig Endotest®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06794424

Intrauterine inseminationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03425604

linzagolix (OBE2109)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT02778399

Expectant managementNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04338035

Three-dimensional (3D) rectal water contrast transvaginal ultrasonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04295343

Computed colonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04295343

A non-invasive blood-based (HerResolve)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07006987

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.